Attention Deficit Hyperactive Disorder (ADHD)
Conditions
Interventions
Experimental group:FocusPro1 digital therapy combined with stable drug therapy
Control group:Stable drug therapy
Sponsors
West China Second Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of ADHD in American Diagnostic and Statistical Manual of Mental Disorders (DSM-V) 5th edition, and have attention deficit or mixed type patients; 2. 6 years of age = 28; 4. CGI-S >= 4 5. Wechsler Intelligence Scale for Children >= 80; 6. Those who were treated with methylphenidate steadily 30 days before joining the group, and kept the original plan and dose to continue treatment during the trial period. 7. Have the conditions to comply with the research plan to complete training and testing and other related requirements; 8. Patients and/or their guardians agree to participate in this study and voluntarily sign the informed consent form. Subjects aged 8 and above should also sign the children's informed consent form.
Exclusion criteria
Exclusion criteria: 1. suffering from neurodevelopmental disorders such as cerebral palsy, epilepsy, adrenal leukodystrophy; 2. Suffering from severe mental illness such as schizophrenia; 3. Hearing impairment leads to similar children's attention deficit-hyperactivity disorder; 4. Patients who are still ineffective after systematic treatment with two different types of ADHD drugs; 5. People who can't use software normally, such as color blindness; 6. past or present game addicts; 7. Recent (within the past 6 months) history of suspected drug abuse or dependence; 8. The movement state reported by family members or observed by researchers that hinders clinical diagnosis and treatment and curative effect observation (such as physical deformity or dysfunction of hands/arms, use of artificial limbs, etc.); 9. Those who had suicidal idea or had serious suicidal impulse judged by researchers; 10. Those who are participating in other clinical trials within 1 month but have not yet left the group; 11. Use ADHD treatment drugs other than methylphenidate within 1 month; 12. Non-drug treatment of ADHD within 1 month; 13. The researcher thinks that it is not suitable for joining the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After 4 weeks of rehabilitation, the response rate of 18 SNAP-IV- Parent Scale was higher than that of baseline training; | — |
Secondary
| Measure | Time frame |
|---|---|
| After 4 weeks, 8 weeks and 3 months of rehabilitation, the evaluation values of 18 SNAP-IV- Parent Scale were improved compared with the baseline values;After 4 weeks, 8 weeks and 3 months of rehabilitation, the measured data of IVA were improved compared with the baseline;After 4 weeks, 8 weeks and 3 months of rehabilitation, the score of WEISS-P (parent version) scale was improved compared with the baseline;Improvement value of TOVA-ACS: measured value of TOVA-ACS-baseline value of tova-ACS after 4 weeks, 8 weeks and 3 months of rehabilitation training;Clinical effect-severity (CGI-S) score changes from baseline and clinical effect-overall improvement (CGI-I) scores at 4 weeks, 8 weeks and 3 months; (CGI-S) improvement value; | — |
Countries
China
Contacts
Public ContactLuo Rong
West China Second Hospital of Sichuan University
Outcome results
None listed